Antibody levels in COVID-19 may decline within 3 months, study finds

Coronavirus antibody levels may plummet within two to three MONTHS, offering only brief immunity to COVID-19, study suggests Researchers at Chongqing Medical studied 37 symptomatic coronavirus patients and 37 symptomatic patients  They found that more than 90% in both groups had sharp declines in their antibody levels within two to three months  Neutralizing antibody levels fell by 11.7 in symptomatic […]

Read more

Antibody Tests Are Still A Long Way From Holding The Key To Ending COVID-19

Novel coronavirus antibody tests can help determine whether a person has contracted COVID-19. COVID-19 antibodies are also being studied to determine if they could hold the key to potential treatments or vaccines. Right now, reliable COVID-19 antibody tests are not widely available, though many are currently in development. Back in mid-March, the coronavirus got me—in a subtle sneak attack. My […]

Read more

Clues to COVID-19 coronavirus’s vulnerability emerge from an antibody against SARS

An antibody recovered from a survivor of the SARS epidemic in the early 2000s has revealed a potential vulnerability of the new coronavirus at the root of COVID-19, according to a study from scientists at Scripps Research. The study, published today in Science, is the first to map a human antibody’s interaction with the new coronavirus at near-atomic-scale resolution. Although […]

Read more

Human antibody reveals hidden vulnerability in influenza virus

The ever-changing “head” of an influenza virus protein has an unexpected Achilles heel, report scientists funded by the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health. The team discovered and characterized the structure of a naturally occurring human antibody that recognizes and disrupts a portion of the hemagglutinin (HA) protein that the virus […]

Read more

Antibody therapy training phagocytes to destroy tumors now tested on patients

Developed by researchers at the University of Turku in Finland, an immunotherapeutic antibody therapy re-educates macrophages to activate passivated cytotoxic T cells to kill cancer. The antibody therapy prevented the growth of tumours in several mouse models, and the development of the therapy has now progressed to patient testing in a phase I/II clinical trial. One reason behind many unsuccessful […]

Read more